Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use

Sponsor
Peking University People's Hospital
Study ID
NCT03491371
Status
Completed

Conditions

  • Efficacy
  • Toxicity

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of three Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated sarcoma.

Key Dates

Start date
Jun 1, 2015
Status verified
Apr 2018
Primary completion
Dec 31, 2016
Completion
Feb 1, 2017

Study Design

Enrollment
56 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: osteosarcoma
    all patients had been given apatinib alone
  • Experimental: Ewing sarcoma
    Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
  • Experimental: soft tissue sarcoma
    Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
  • Experimental: Chondrosarcoma
    Patients were given apatinib alone

Primary Outcome Measure

objective response rate [ Time Frame: 3 month ]

Related Studies